Clinical and optical coherence tomography biomarkers as prognostic factors in dexamethasone intravitreal implant for diabetic macular edema.

IF 1.4 4区医学 Q3 OPHTHALMOLOGY

European Journal of Ophthalmology Pub Date : 2024-11-01 Epub Date: 2024-02-21 DOI:10.1177/11206721241235242

Giovanni William Oliverio, Alessandro Meduri, Valentina Urzì Brancati, Irene Ingrande, Laura De Luca, Enrico Di Raimondo, Letteria Minutoli, Emanuela Aragona, Pasquale Aragona

{"title":"Clinical and optical coherence tomography biomarkers as prognostic factors in dexamethasone intravitreal implant for diabetic macular edema.","authors":"Giovanni William Oliverio, Alessandro Meduri, Valentina Urzì Brancati, Irene Ingrande, Laura De Luca, Enrico Di Raimondo, Letteria Minutoli, Emanuela Aragona, Pasquale Aragona","doi":"10.1177/11206721241235242","DOIUrl":null,"url":null,"abstract":"Purpose: Aim of the study was to evaluate the efficacy of dexamethasone (DEX) 0.7 mg intravitreal implant in patients with diabetic macular edema (DME) and serous retinal detachment (SRD), and to study the prognostic factors on a follow up of 12 months.Methods: Forty eyes of twenty- six patients with centre involving DME and SRD, who underwent DEX implant, were enrolled. Best-corrected visual acuity (BCVA), Swept source OCT imaging and intraocular pressure were evaluated. Central macular thickness (CMT), vitreomacular adhesion (VMA), disorganization of retinal inner layers (DRILs), hyperreflective dots (HRD), SRD and ellipsoid zone (EZ) disruption were included in the analysis at baseline and 12 months after implant.Results: According to our parametric analysis, at 12 months, BVCA improvement from 48.6 ± 23.4 letters to 53.3 ± 24.5 letters was statistically significant (p = 0.04), CMT decreased from 460 ± 99.52 μm to 322.9 ± 117 μm. The presence at baseline of VMA (p = 0.01), EZ disruption (p = 0.03) and DRILs (p = 0.04), were associated with poor BCVA improvement at the end of follow-up.Conclusion: In conclusion, OCT biomarkers can be considered significant prognostic factors for treatment outcome in patients with DME undergoing DEX intravitreal implant.","PeriodicalId":12000,"journal":{"name":"European Journal of Ophthalmology","volume":null,"pages":null},"PeriodicalIF":1.4000,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Journal of Ophthalmology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/11206721241235242","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/2/21 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"OPHTHALMOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose: Aim of the study was to evaluate the efficacy of dexamethasone (DEX) 0.7 mg intravitreal implant in patients with diabetic macular edema (DME) and serous retinal detachment (SRD), and to study the prognostic factors on a follow up of 12 months.

Methods: Forty eyes of twenty- six patients with centre involving DME and SRD, who underwent DEX implant, were enrolled. Best-corrected visual acuity (BCVA), Swept source OCT imaging and intraocular pressure were evaluated. Central macular thickness (CMT), vitreomacular adhesion (VMA), disorganization of retinal inner layers (DRILs), hyperreflective dots (HRD), SRD and ellipsoid zone (EZ) disruption were included in the analysis at baseline and 12 months after implant.

Results: According to our parametric analysis, at 12 months, BVCA improvement from 48.6 ± 23.4 letters to 53.3 ± 24.5 letters was statistically significant (p = 0.04), CMT decreased from 460 ± 99.52 μm to 322.9 ± 117 μm. The presence at baseline of VMA (p = 0.01), EZ disruption (p = 0.03) and DRILs (p = 0.04), were associated with poor BCVA improvement at the end of follow-up.

Conclusion: In conclusion, OCT biomarkers can be considered significant prognostic factors for treatment outcome in patients with DME undergoing DEX intravitreal implant.

查看原文本刊更多论文

作为地塞米松玻璃体内植入治疗糖尿病性黄斑水肿预后因素的临床和光学相干断层扫描生物标志物

目的：该研究旨在评估地塞米松（DEX）0.7 毫克玻璃体内植入对糖尿病性黄斑水肿（DME）和浆液性视网膜脱离（SRD）患者的疗效，并研究随访 12 个月的预后因素：方法：研究对象包括26名接受DEX植入术的中心性糖尿病黄斑水肿和浆液性视网膜脱离患者的40只眼睛。对最佳矫正视力（BCVA）、扫描源 OCT 成像和眼压进行了评估。黄斑中心厚度（CMT）、玻璃体粘连（VMA）、视网膜内层紊乱（DRILs）、超反光点（HRD）、SRD和椭圆体区（EZ）破坏也包括在基线和植入后12个月的分析中：根据我们的参数分析，12 个月后，BVCA 从 48.6 ± 23.4 个字母提高到 53.3 ± 24.5 个字母，具有统计学意义（p = 0.04），CMT 从 460 ± 99.52 μm 降低到 322.9 ± 117 μm。基线存在VMA（p = 0.01）、EZ破坏（p = 0.03）和DRILs（p = 0.04）与随访结束时BCVA改善不佳有关：总之，OCT 生物标志物可被视为接受 DEX 玻璃体内植入术的 DME 患者治疗结果的重要预后因素。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

European Journal of Ophthalmology 医学-眼科学

CiteScore

3.60

自引率

0.00%

发文量

372

审稿时长

3-8 weeks

期刊介绍： The European Journal of Ophthalmology was founded in 1991 and is issued in print bi-monthly. It publishes only peer-reviewed original research reporting clinical observations and laboratory investigations with clinical relevance focusing on new diagnostic and surgical techniques, instrument and therapy updates, results of clinical trials and research findings.